"In pursuance of the Emergency Use Authorisation of its Covid-19 vaccine, Pfizer participated in the Subject Expert Committee meeting of the Drug Regulatory Authority of India on February 3. Based on the deliberations at the meeting and our understanding of additional information that the regulator may need, the company has decided to withdraw its application at this time," a Pfizer spokesperson said.
"Pfizer will continue to engage with the authority and resubmit its approval request with additional information as it becomes
SEE ALSO:
How big is India's debt and should it be a worry?
Here's why you aren't being able to apply for Brookfield REIT IPO through Zerodha, Groww and other stockbroking apps